Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15682807 | 0.89 | POLRMT (0.30) | POLRMT | |
| SCHEMBL9912348 | 0.85 | DOT1L (0.30) | — | |
| SCHEMBL11924463 | 0.85 | DOT1L (0.30) | — | |
| SCHEMBL15682884 | 0.78 | — | — | |
| SCHEMBL17525198 | 0.78 | — | — | |
| SCHEMBL17522683 | 0.78 | POLRMT (0.42) | POLRMT | |
| SCHEMBL15605849 | 0.77 | DOT1L (0.34) | POLRMT | |
| SCHEMBL10100412 | 0.77 | — | — | |
| SCHEMBL13471043 | 0.77 | POLRMT (0.49) | POLRMT | |
| SCHEMBL13471155 | 0.77 | POLRMT (0.49) | POLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9457039-B2 | 2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160045526-A1 | 2'-DISUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2016-02-18 | — | — | US | disclosed |
| WO-2014059902-A1 | 2'-DISUBSTITUTED SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045526-A1 | 2'-DISUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SLC28A2, SLC28A1, SLC29A2 | POLRMT 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.